Genmab — September 2020

[kkjoel]

Ok. Could be quite a large amount GEN gets out of this, I suppose. We'll see - excitedly awaiting.....

[E_L]

@lahn1 i only know they are in the same location https://www.utrechtsciencepark.nl/en/home/about-the-park/news/immunoprecise-antibodies-collaborates-in-life-sciences-in-the-netherlands

[StockBull]

Der er jo nærmest kunst med de streger. Ufatteligt så precist kursen følger retningen mod de 2550 som kunne være target inden næste retracement https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/86954_Kunst.JPG

[Mcjean]

Sejt! hvordan ser stregerne ud oppe ved 10.000-området? Er det ren fibonacci tilsat lidt Per Arnoldi kruseduller eller er vejen ryddet til snarlig end-station?:-D

[lahn1]

@EL Thx

[StockBull]

Har været på Vincent van Gogh museumet i Amsterdam og efter dette besøg er det gået meget godt med stregerne 5000 er mulig i Q1 2022 såfremt kursen holder sig inde i kanalen, meeen Genmab er nok opkøbt inden med 50% premium

[Rune2494]

Hvordan lyder raslen på vandrørene i forhold til takeover efterhånden? Udover herinde i chatten er der godt nok langt imellem, at jeg hører
nogen gisne om det

[Darvin]

EL and kkjoel - Do not think now it should be read as if Genmab is on its way out. It addresses the risks associated with investing in ADCT. The probability is probably primarily that the parties reach an agreement regarding license and the financial. If they do not agree, a divestment process can start. I wonder if it is most likely that they will agree on license terms. BTW If not - Genmab also has the option to take over.

[Mcjean]

@Stockbull, Ja det bliver så et dyrt opkøb, men det er ved at være sidste udkald for de store, de får ikke Genmab med 50%, hvis deres nye guldæg virker, så får de slet ikke Genmab, så vil de blive blandt de allerstørste inden for feltet, måske endda de største.

[E_L]

@Darvin the Berlin hospital where the Lupus patients were treated will also start a Daratumumab Lupus trial https://www.charite.de/service/pressemitteilung/artikel/detail/autoimmunerkrankungen_gezielt_behandeln/

[E_L]

and @Bulder ; given that "Studienleiter" was Dr. Alexander, "Leiter der rheumatologischen Fachambulanz" I imagine RA could follow soon

[Bulder]

Yes, but I would prefer a large Janssen-led study in RA.

[E_L]

offcourse, so would I. However, I am wondering more and more if maybe JNJ will wait for early efficacy of HexabodyCD38 before deciding what they will do with any new CD38 trials...
?

[gentogen]

From previous link: If the Parties mutually agree on a Term Sheet by 31 August 2020, the Parties shall negotiate in good faith a license agreement in accordance with the Term Sheet for a period of sixty (60) calendar days starting on 1 September 2020, which sixty (60) calendar day period may be extended by prior mutual written agreement by the Parties (the “Negotiation Period”).

[gentogen]

If we fail to agree on the key financial terms or if no license agreement has been entered into during the specified time period to do so, a defined process to facilitate the divestment of Cami will be initiated. This process includes the opportunity for both parties to bid for the license rights alongside third parties

[Darvin]

Præcis

[E_L]

i don't think that stops the divestment process of the 25%? and then there is still the Genmab antibody they will want royalties/licence payments on

[KWC]

FDA Accepts BLA for bluebird and BMS' Multiple Myeloma CAR-T Treatment

[KWC]

https://www.biospace.com/article/fda-accepts-bla-for-bms-and-bluebird-s-bla-for-multiple-myeloma-car-t-under-priority-review/?utm_campaign=Daily Article&utm_content=140594344&utm_medium=social&utm_source=facebook&hss_channel=fbp-10530620221

[BioShare]

Der var så ikke helt enighed om aftalen og betalingen til HALO for SC https://finance.yahoo.com/news/genmab-commences-bindin
g-arbitration-two-210400349.html